THE ULTIMATE GUIDE TO LDN-27219 AS A CANCER DRUG CANDIDATE

One significantly appealing compound is LDN-27219. Even though most tTG inhibitors are made to bind towards the protein crosslinking Lively internet site, LDN-27219 alternatively binds towards the nucleotide binding pocket of the enzyme when it's in its shut-state conformation, and stabilizes that conformation to circumvent crosslinking activity.78